Company intelligence / Profile preview

CanAg Diagnostics

Ownership: Private
Development stage: Commercial

Overview

CanAg Diagnostics developed and commercialized high-quality monoclonal antibodies and enzyme immunoassay kits for the detection of biochemical markers associated with common solid cancers. Their products are widely used in clinical laboratories for oncology diagnostics. The company was acquired by Fujirebio Diagnostics in May/June 2006 to expand global offerings in oncology biomarker testing.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyImmunological reagent (for diagnostics)Enzyme immunoassay kit (EIA kit)
Industry: Protein Biomarker Diagnostics

Partnerships

Major global diagnostics companies via supply agreements/licensing; specifics not listed but referenced as long-standing relationships with major industry players

Beyond the preview

Go deeper on CanAg Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CanAg Diagnostics.

Explore the full profile